We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VWF

News List

Researchers in Ireland identify the reason COVID-19 patients develop blood clots expresspharma
June 18, 2021
The blood of COVID-19 patients had higher levels of the pro-clotting VWF molecules and lower levels of the anti-clotting ADAMTS13.
Researchers identify why Covid-19 patients develop life-threatening clots firstwordpharma
June 16, 2021
Scientists have identified how and why some Covid-19 patients can develop life-threatening clots, which could lead to targeted therapies that prevent this from happening.
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI [von Willebrand factor (Recombinant)] firstwordpharma
June 15, 2021
Takeda Pharmaceutical Company Limited announced today that FDA has accepted for review the sBLA) for VONVENDI® [von Willebrand factor (Recombinant)] for prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults.